Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Annika, Herr"'
Autor:
Ariel D Stern, PhD, Jan Brönneke, LLM, Jörg F Debatin, MD, Julia Hagen, MPA, Henrik Matthies, PhD, Smit Patel, PharmD, Ieuan Clay, PhD, Bjoern Eskofier, ProfPhD, Annika Herr, ProfPhD, Kurt Hoeller, PhD, Ashley Jaksa, MPH, Daniel B Kramer, MD, Mattias Kyhlstedt, Katherine T Lofgren, PhD, Nirosha Mahendraratnam, PhD, Holger Muehlan, PhD, Simon Reif, PhD, Lars Riedemann, MD, Jennifer C Goldsack, MA
Publikováno v:
The Lancet: Digital Health, Vol 4, Iss 3, Pp e200-e206 (2022)
Summary: In 2019, Germany passed the Digital Healthcare Act, which, among other things, created a “Fast-Track” regulatory and reimbursement pathway for digital health applications in the German market. The pathway explicitly provides for flexibil
Externí odkaz:
https://doaj.org/article/946b756032bc47a5b92f1ed2d9bfbfbd
Publikováno v:
Public Health Forum. 30:190-192
Zusammenfassung Mithilfe eines präferenzbasierten Indexinstruments zur Messung der Pflegeheimqualität kann die gesundheitsökonomische Evaluation von Pflegeleistungen erleichtert und die Perspektive der Nutzer:innen stärker als bisher in die Bewer
Publikováno v:
Health economicsREFERENCES. 32(2)
This paper evaluates the causal effects of changes in reference prices (RP) on prices, copayments, and overall expenditures for off-patent pharmaceuticals. With reference pricing, firms set prices freely and the health plan covers the expenses only u
Autor:
Annika Herr, Jona T. Stahmeyer, Sveja Eberhard, Melissa Hemmerling, Siegbert Rossol, Henning Weseloh, Jan Zeidler, Birte Burger, Christian Krauth
Publikováno v:
Zeitschrift für Gastroenterologie. 59:851-858
Zusammenfassung Hintergrund Die nichtalkoholische Fettlebererkrankung (NAFLD) zählt zu den häufigsten Lebererkrankungen in Deutschland. Langfristig besteht das Risiko einer Leberzirrhose und weiterer Folgeerkrankungen. Epidemiologische Studien zur
Many countries limit public and private reimbursement for nursing care costs for social or financial reasons. Still, quality varies across nursing homes. We explore the causal link between case-mix adjusted nurse staffing ratios as an indicator of ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a14f710be283a2808493c2ad1f34f298
https://hdl.handle.net/10419/265078
https://hdl.handle.net/10419/265078
Autor:
Ariel D Stern, Jan Brönneke, Jörg F Debatin, Julia Hagen, Henrik Matthies, Smit Patel, Ieuan Clay, Bjoern Eskofier, Annika Herr, Kurt Hoeller, Ashley Jaksa, Daniel B Kramer, Mattias Kyhlstedt, Katherine T Lofgren, Nirosha Mahendraratnam, Holger Muehlan, Simon Reif, Lars Riedemann, Jennifer C Goldsack
Publikováno v:
The Lancet. Digital health. 4(3)
In 2019, Germany passed the Digital Healthcare Act, which, among other things, created a "Fast-Track" regulatory and reimbursement pathway for digital health applications in the German market. The pathway explicitly provides for flexibility in how re
Publikováno v:
Health Affairs. 38:1182-1187
The 2011 German Pharmaceutical Market Restructuring Act subjected brand-name drugs for nonrare diseases to price regulation based on an assessment of their clinical benefit. Indication-specific assessment outcomes range from major added benefit to le
Autor:
Hans-Theo Normann, Annika Herr
Publikováno v:
Journal of Economic Behavior & Organization. 158:367-378
Giving registered organ donors priority on organ waiting list can substantially increase the number of donors and save lifes. Evidence for these effects comes from recent experiments that implemented such priority rules in abstract laboratory environ
Autor:
Jona T, Stahmeyer, Melissa, Hemmerling, Birte, Burger, Sveja, Eberhard, Christian, Krauth, Jan, Zeidler, Annika, Herr, Henning, Weseloh, Siegbert, Rossol
Publikováno v:
Zeitschrift fur Gastroenterologie. 59(8)
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases in Germany. In the long term, there is an increased risk of developing liver cirrhosis and subsequent diseases. Epidemiologic studies on NAFLD prevalence in Ge
Autor:
Annika Herr, Moritz Suppliet
Publikováno v:
Journal of Health Economics, 56, 19-29. Elsevier Science BV
Health insurance companies curb price-insensitive behavior and the moral hazard of insureds by means of cost-sharing, such as tiered co-payments or reference pricing in drug markets. This paper evaluates the effect of price limits - below which drugs